评估用于淋巴瘤227Th/89Zr配对放射免疫治疗的候选诊疗一体化药物
研究以靶向CD20的奥法木单抗为载体,比较4种双功能螯合剂对227Th4+的螯合性能,用于α粒子放射治疗与放射诊疗一体化。L804螯合剂可在高产率、高纯度、高比活度(8 GBq/g)下快速结合227Th并具延长的稳定性;89Zr-L804-奥法木单抗的器官分布与227Th一致,可 delineate SU-DHL-6 肿瘤。L804螯合剂可用于89Zr/227Th定量成像与α粒子治疗的强效放射诊疗一体化。
要点
- L804螯合剂快速高效结合227Th,产率、纯度与比活度(8 GBq/g)均高且稳定性延长。
- 227Th-L804-奥法木单抗在体内肿瘤靶向中验证了该螯合剂的效用。
- 89Zr-L804-奥法木单抗的器官分布与227Th一致,可 delineate SU-DHL-6 肿瘤。
核心结论
- 市售与新型227Th螯合剂性能各异,L804螯合剂可用于89Zr/227Th定量成像与α粒子治疗的强效放射诊疗一体化。
研究设计与样本
- 以靶向CD20的奥法木单抗为载体,比较4种双功能螯合剂(p-SCN-Bn-DOTA、p-SCN-Bn-HEHA、DFOcyclo*-p-Phe-NCS、L804-NHS)制备钍放射药物的性能,并在体外与体内评估产率、纯度与稳定性。
- 在表达CD20的模型中开展先导227Th标记化合物的体内肿瘤靶向,并与配套的89Zr标记PET药物比较。
主要发现
- 227Th标记的奥法木单抗-螯合剂构建体除HEHA外放射化学纯度均超过95%。
- 227Th-HEHA-奥法木单抗体外稳定性中等。
- 227Th-DFOcyclo*-奥法木单抗227Th标记效率极佳,但体内显示肝与脾高摄取,提示聚集。
- 227Th-DOTA-奥法木单抗标记差,产率不超过5%,比活度低(0.08 GBq/g),长期体外稳定性有限(<80%)。
- 227Th-L804-奥法木单抗在高产率、纯度与比活度(8 GBq/g)下快速高效结合227Th,并显示延长的稳定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
227Th is a promising radioisotope for targeted α-particle therapy. It produces 5 α-particles through its decay, with the clinically approved 223Ra as its first daughter. There is an ample supply of 227Th, allowing for clinical use; however, the chemical challenges of chelating this large tetravalent f-block cation are considerable. Using the CD20-targeting antibody ofatumumab, we evaluated chelation of 227Th4+ for α-particle-emitting and radiotheranostic applications. Methods: We compared 4 bifunctional chelators for thorium radiopharmaceutical preparation: S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), 2-(4-isothicyanatobenzyl)-1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid (p-SCN-Bn-HEHA), p-isothiacyanatophenyl-1-hydroxy-2-oxopiperidine-desferrioxamine (DFOcyclo*-p-Phe-NCS), and macrocyclic 1,2-HOPO N-hydroxysuccinimide (L804-NHS). Immunoconstructs were evaluated for yield, purity, and stability in vitro and in vivo. Tumor targeting of the lead 227Th-labeled compound in vivo was performed in CD20-expressing models and compared with a companion 89Zr-labeled PET agent. Results: 227Th-labeled ofatumumab-chelator constructs were synthesized to a radiochemical purity of more than 95%, excepting HEHA. 227Th-HEHA-ofatumumab showed moderate in vitro stability. 227Th-DFOcyclo*-ofatumumab presented excellent 227Th labeling efficiency; however, high liver and spleen uptake was revealed in vivo, indicative of aggregation. 227Th-DOTA-ofatumumab labeled poorly, yielding no more than 5%, with low specific activity (0.08 GBq/g) and modest long-term in vitro stability (<80%). 227Th-L804-ofatumumab coordinated 227Th rapidly and efficiently at high yields, purity, and specific activity (8 GBq/g) and demonstrated extended stability. In vivo tumor targeting confirmed the utility of this chelator, and the diagnostic analog, 89Zr-L804-ofatumumab, showed organ distribution matching that of 227Th to delineate SU-DHL-6 tumors. Conclusion: Commercially available and novel chelators for 227Th showed a range of performances. The L804 chelator can be used with potent radiotheranostic capabilities for 89Zr/227Th quantitative imaging and α-particle therapy.
引用
- Abou DS, Longtine M, Fears A, et al. Evaluation of Candidate Theranostics for 227Th/89Zr Paired Radioimmunotherapy of Lymphoma. J Nucl Med. 2023. PMID: 37142300. doi:10.2967/jnumed.122.264979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。